Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases

Jasim SA., Yumashev AV., Abdelbasset WK., Margiana R., Margiana R., Margiana R.

Narrative Review on Type 1 Diabetes, Neuroinflammation, Chronic Inflammation, Immune Modulation, published in Stem Cell Res Ther (2022) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Stem Cell Res Ther (2022)
Reported sample size
—
Source database
Europe PMC
PMID
35255979
PMCID
PMC8900359
DOI
10.1186/s13287-022-02782-7
Citations
67

Abstract (original English)

The autoimmune diseases are associated with the host immune system, chronic inflammation, and immune reaction against self-antigens, which leads to the injury and failure of several tissues. The onset of autoimmune diseases is related to unbalanced immune homeostasis. Mesenchymal stem cells (MSCs) are multipotent cells which have capability to self-renew and differentiate into various cell types that exert a critical role in immunomodulation and regenerative therapy. Under the certain condition in vitro, MSCs are able to differentiate into multiple lineage such as osteoblasts, adipocytes, and neuron-like cells. Consequently, MSCs have a valuable application in cell treatment. Accordingly, in this review we present the last observations of researches on different MSCs and their efficiency and feasibility in the clinical treatment of several autoimmune disorders including rheumatoid arthritis, type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, autoimmune liver disease, and Sjogren's syndrome.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsHumansLupus Erythematosus, SystemicAutoimmune DiseasesMesenchymal Stem Cell TransplantationImmunomodulation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research